Press releases
- BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
- Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
- BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
- BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- BeiGene to Present at Upcoming Investor Conferences
More ▼
Key statistics
On Friday, Beigene Ltd (688235:SHH) closed at 130.77, 32.76% above the 52 week low of 98.50 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 129.78 |
---|---|
High | 131.50 |
Low | 129.15 |
Bid | 130.72 |
Offer | 130.77 |
Previous close | 129.20 |
Average volume | 1.62m |
---|---|
Shares outstanding | 1.36bn |
Free float | 1.28bn |
P/E (TTM) | -- |
Market cap | 120.78bn CNY |
EPS (TTM) | -5.25 CNY |
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼